AstraZeneca announces Evusheld long-acting antibody combination approved in the EU for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population
AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been granted marketing authorisation in the European Union (EU) for the pre-exposure…
